$TREX

Trex reported Q3 2026 net sales of $359.5M, up 26% YoY, with net income of $52.5M. The company raised its 2026 guidance to $1.296B-$1.306B in net sales and $355M-$360M in adjusted EBITDA. Growth was driven by product lines and market share gains, with new distribution partnerships and facility expansions underway.

TREX CO INC (TREX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News release TREX COMPANY REPORTS Strong Third QUARTER 2026 RESULTS, DELIVERING BACK-TO-BACK RECORD QUARTERS 26% Net Sales Growth Drives Record High Third Quarter Revenue Sales Driven by Broad Strength Led by Wood Conversion Focus Successfully Executing Enhanced Dist

Trex Company celebrated 30 years in business by ringing the opening bell on the NYSE. The company, which produces wood-alternative composite decking, expects to reach $2 billion in annual revenue by 2030 and projects 2026 revenue between $1.21 billion and $1.25 billion. Trex plans to have its Little Rock facility operating at 50% capacity by the end of the year.

TD Cowen upgraded BlackRock (BLK) to Buy with a $1,405 price target, citing potential for $100+ EPS. Stifel upgraded Trex (TREX) to Buy with a $55 target, noting its premium valuation. Wells Fargo upgraded Venture Global (VG) to Overweight with a $21 target, citing AI data center strategy. BTIG upgraded American Electric (AEP) to Buy with a $147 target. Loop Capital downgraded Apple (AAPL) to Hold with a $330 target, citing iPhone shipment cuts.

Analysts updated ratings and price targets for several companies. Apple (AAPL) was downgraded to hold with a reduced target. BlackRock (BLK) was upgraded to buy with a higher target. Other companies affected include Telkonet, Alcoa, and Skydance.

Stifel upgraded Trex (NYSE:TREX) to Buy, raising its price target to $55. The firm cited strong demand momentum, pricing power, and a positive outlook for EBITDA growth. Trex reported Q2 2026 revenue of $418M, beating estimates, but investors expressed concerns about near-term outlook and margins. Deutsche Bank also upgraded Trex to Buy with a $57 price target.

Multi-Trex Integrated Foods Plc's shares rose 16.67% after the Nigerian Exchange Limited (NGX) lifted an eight-year trading suspension. The stock increased from N0.36 to N0.42 per share, ranking among the top five gainers on the NGX. The suspension was lifted after Multi-Trex filed required financial statements, resuming trading activity. The stock was highly traded, with over 27 million shares exchanged. This occurred amid a broader market decline, with the NGX All-Share Index falling 0.97%.

TRex Bio Inc. raised $116.7 million in its U.S. IPO, pricing shares at $14, the bottom of its $14-$16 range. The biotech company sold 8.3 million shares, giving it a market value of about $384 million. Proceeds will fund clinical trials for its lead drug candidate, TRB-061. Shares will trade on Nasdaq under the ticker TRXB. The company reported a net loss of $34.8 million in 2025, up from $3.1 million the prior year.

TRex Bio priced its IPO at $117M, selling 8.3M shares at $14 each, and will trade on Nasdaq under 'TRXB'. The company is developing immune drugs, with TRB-061 in Phase 1 trials and TRB-071 planned for testing. Eli Lilly, its largest shareholder, may also buy IPO shares. TRex has raised $220M in venture financing. Another biotech, Retension Pharmaceuticals, also went public with a $45M offering, highlighting increased biotech IPO activity in 2026.

Deutsche Bank upgraded Trex (TREX) to Buy, raising its price target to $57. The firm cited high-single digit sales growth in Q2 2026 and potential for double-digit top-line growth in the second half of 2026. Trex reported Q2 2026 revenue of $418 million, up 8% year-over-year, and adjusted EPS of $0.62. The stock has gained 25% year-to-date and trades at $43.82, below its Fair Value according to InvestingPro data. Management targets $2 billion in sales by 2028, with a 12% CAGR.